<DOC>
	<DOCNO>NCT00667420</DOCNO>
	<brief_summary>A pilot study determine safety use perioperative panitumumab EOX ( epirubicin , oxaliplatin , capecitabine ) patient adenocarcinoma esophagus stomach .</brief_summary>
	<brief_title>Perioperative Panitumumab Epirubicin , Oxaliplatin Xeloda ( EOX ) Patients With Gastroesophageal Adenocarcinoma</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Patients must histologically cytologically confirm diagnosis adenocarcinoma stomach , gastroesophageal junction , low third esophagus , AJCC stage IIIIIB ( gastric ) IIAIVA ( esophageal ) . M1a disease include , T4 lesion . No prior radiation chemotherapy include antiEGFR vascular endothelial growth factor ( VEGF ) antibody tyrosine kinase inhibitor treatment . All patient must stag endoscopic ultrasound ( EUS ) prior enrollment . Men Women &gt; 18 year Age ECOG performance status &lt; 2 ( Karnofsky &gt; 60 % , see Appendix A ) . Cardiac ejection fraction &gt; 45 % echocardiogram MUGA scan . Must able either swallow pill gastrostomy tube place administration enteral medication . Patients must normal organ , metabolic marrow function define : Hematologic function , follow : Absolute neutrophil count ( ANC ) ≥ 1.5 x 109/L Platelet count ≥ 100 x 109/L Hemoglobin ≥ 9.0 g/dL Renal function , follow : Creatinine &lt; = 1.5 mg/dL x ULN Hepatic function , follow : Aspartate aminotransferase ( AST ) Alanine aminotransferase ( ALT ) &lt; = 3 x ULN Total bilirubin &lt; 1.5 x ULN Metabolic function , follow : Magnesium ≥ low limit normal Calcium &lt; = low limit normal Human IgG know cross placental barrier ; therefore , Panitumumab may transmit mother develop fetus . In woman childbearing potential , appropriate contraceptive measure must use treatment panitumumab 6 month follow last dose panitumumab . If panitumumab use pregnancy patient become pregnant receive drug , apprise potential risk loss pregnancy potential hazard fetus . 3.1.10 Ability understand willingness sign date write IEC/IRB approve informed consent form . Evidence distant metastatic disease . T4 tumor initial stag study . History another primary cancer , except : Curatively treat situ cervical cancer Curatively resect nonmelanoma skin cancer Other primary solid tumor curatively treat know active disease present treatment administer ³ 5 year prior enrollment Relative absolute contraindication surgery opinion investigator make patient poor candidate surgical resection . History allergic reaction attribute compound similar chemical biologic composition panitumumab agent use study . Subjects require chronic use immunosuppressive agent ( e.g. , methotrexate , cyclosporine ) . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . History interstitial lung disease e.g . pneumonitis pulmonary fibrosis evidence interstitial lung disease baseline chest CT scan . History medical psychiatric condition laboratory abnormality opinion investigator may increase risk associate study participation investigational product ( ) administration may interfere interpretation result . Subject unwilling unable comply study requirement . Women test positive serum urine pregnancy test &lt; 72 hour randomization breast feeding . Known positive test ( ) human immunodeficiency virus infection , hepatitis C virus , acute chronic active hepatitis B infection . Major surgery 28 day minor surgery within 14 day study enrollment . Men woman childbearing potential ( woman postmenopausal &lt; 52 week , surgically sterilize , abstinent ) consenting use adequate contraception ( per institutional standard care ) course study last investigational product ( ) administration ( 24 week woman , 4 week men ) . Subjects &gt; grade 1 neuropathy baseline . Contraindication portacath placement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>gastric</keyword>
	<keyword>esophageal</keyword>
	<keyword>panitumumab</keyword>
</DOC>